Professor Avril Robertson
Professor

Avril Robertson

Email: 
Phone: 
+61 7 334 60586

Availability

Professor Avril Robertson is:
Available for supervision

Qualifications

  • Masters (Research), University of St Andrews
  • Doctor of Philosophy, University of St Andrews
  • Postgraduate Diploma in Higher Education, The University of Queensland
  • Postgraduate Diploma in Higher Education, Institution to be confirmed

Search Professor Avril Robertson’s works on UQ eSpace

134 works between 1999 and 2025
All (134) Journal Article (99) Book Chapter (1) Conference Publication (27) Other Outputs (7)

121 - 134 of 134 works

2014

Conference Publication

What causes Kupffer cell activation in NAFLD? HMGB1, TLR4, crystals and NLRP3 inflammasome link free cholesterol to inhibitable pro-inflammatory pathways in NASH

Gan, L. T., Van Rooyen, D. M., Cooper, M., Robertson, A., Masters, S., Teoh, N. and Farrell, G. (2014). What causes Kupffer cell activation in NAFLD? HMGB1, TLR4, crystals and NLRP3 inflammasome link free cholesterol to inhibitable pro-inflammatory pathways in NASH. Australian Gastroenterology Week, Broadbeach, QLD, Australia, 22-24 october 2014. Richmond, VIC, Australia: Wiley-Blackwell Publishing Asia. doi: 10.1111/jgh.12736

What causes Kupffer cell activation in NAFLD? HMGB1, TLR4, crystals and NLRP3 inflammasome link free cholesterol to inhibitable pro-inflammatory pathways in NASH

2014

Conference Publication

Novel Compound Cytokine Release Inhibitory Drug 3 (CRID3) Inhibits the NLRP3 Inflammasome in Rheumatoid Arthritis

McGarry, Trudy, Connolly, Mary, Coll, Rebecca C., Robertson, Avril A. B., Cooper, Matthew A., O'Neill, Luke A., Veale, Douglas J. and Fearon, Ursula (2014). Novel Compound Cytokine Release Inhibitory Drug 3 (CRID3) Inhibits the NLRP3 Inflammasome in Rheumatoid Arthritis. 78th Annual Meeting of the American College of Rheumatology/49th Annual Meeting of the Association of Rheumatology Health Professionals, Boston, MA United States, 14-19 November 2014. Hoboken, NJ United States: John Wiley and Sons.

Novel Compound Cytokine Release Inhibitory Drug 3 (CRID3) Inhibits the NLRP3 Inflammasome in Rheumatoid Arthritis

2014

Conference Publication

MCC950 is a potent and specific inhibitor of the NLRP3 inflammasome and a novel potential therapeutic for NLRP3 driven diseases

Coll, Rebecca C., Robertson, Avril A. B., Chae, Jae Jin, Higgins, Sarah C., Dungan, Lara S., Munoz-Planillo, Raul, Monks, Brian G., Croker, Daniel E., Sutton, Caroline E., Stutz, Andrea, Nunez, Gabriel, Latz, Eicke, Kastner, Daniel L., Mills, Kingston H. G., Masters, Seth L., Schroder, Kate, Cooper, Matt A. and O'Neill, Luke A. J. (2014). MCC950 is a potent and specific inhibitor of the NLRP3 inflammasome and a novel potential therapeutic for NLRP3 driven diseases. 2nd Annual Meeting of the International-Cytokine-and-Interferon-Society (ICIS), Melbourne Australia, Oct 26-29, 2014. London United Kingdom: Academic Press. doi: 10.1016/j.cyto.2014.07.037

MCC950 is a potent and specific inhibitor of the NLRP3 inflammasome and a novel potential therapeutic for NLRP3 driven diseases

2013

Journal Article

Erratum: The cytokine release inhibitory drug CRID3 targets ASC oligomerisation in the NLRP3 and AIM2 inflammasomes

Coll, R. C., Robertson, A. A.B., Butler, M., Cooper, M. and O'Neill, L. A.J. (2013). Erratum: The cytokine release inhibitory drug CRID3 targets ASC oligomerisation in the NLRP3 and AIM2 inflammasomes. PLoS ONE, 8 (7) e29539. doi: 10.1371/annotation/78d328b9-2c8c-4978-84b1-7e6a0b12ada1

Erratum: The cytokine release inhibitory drug CRID3 targets ASC oligomerisation in the NLRP3 and AIM2 inflammasomes

2013

Journal Article

Efficient synthesis of anacardic acid analogues and their antibacterial activities

Mamidyala, Sreeman K., Ramu, Soumya, Huang, Johnny X., Robertson, Avril A. B. and Cooper, Matthew A. (2013). Efficient synthesis of anacardic acid analogues and their antibacterial activities. Bioorganic & Medicinal Chemistry Letters, 23 (6), 1667-1670. doi: 10.1016/j.bmcl.2013.01.074

Efficient synthesis of anacardic acid analogues and their antibacterial activities

2011

Journal Article

The cytokine release inhibitory drug CRID3 targets ASC oligomerisation in the NLRP3 and AIM2 inflammasomes

Coll, Rebecca C., Robertson, Avril, Butler, Mark, Cooper, Matthew and O'Neill, Luke A. J. (2011). The cytokine release inhibitory drug CRID3 targets ASC oligomerisation in the NLRP3 and AIM2 inflammasomes. PLoS ONE, 6 (12) e29539, e29539. doi: 10.1371/journal.pone.0029539

The cytokine release inhibitory drug CRID3 targets ASC oligomerisation in the NLRP3 and AIM2 inflammasomes

2007

Conference Publication

The synthesis of isotopically labelled glucosinolates for analysis and metabolic studies

Botting, Nigel P., Robertson, Avril A. B. and Morrison, John J. (2007). The synthesis of isotopically labelled glucosinolates for analysis and metabolic studies. Ninth International Symposium on the Synthesis and Applications of Isotopically Labelled Compounds, Edinburgh, Scotland, United Kingdom, 16–20 July 2006. Bognor Regis, West Sussex, United Kingdom: John Wiley & Sons. doi: 10.1002/jlcr.1225

The synthesis of isotopically labelled glucosinolates for analysis and metabolic studies

2006

Journal Article

The synthesis of glucosinolates deuterium labelled in the glucose fragment

Robertson, Avril and Botting, Nigel P. (2006). The synthesis of glucosinolates deuterium labelled in the glucose fragment. Journal of Labelled Compounds and Radiopharmaceuticals, 49 (13), 1201-1211. doi: 10.1002/jlcr.1141

The synthesis of glucosinolates deuterium labelled in the glucose fragment

2005

Other Outputs

Preparation of aroyl-O-piperidine derivatives as microsomal triglyceride transfer protein (MTP) and/or apoprotein B (ApoB) inhibitors useful in the treatment of dyslipidemia and related diseases

Dumas, Herve, Barbanton, Jacques, Collonges, Francois, Decerprit, Jacques, Ortholand, Jean-Yves, Benzies, David, Cameron, Stuart, Foster, Richard, Guessregen, Stefan, Kane, Peter, Lainton, Julia, Robertson, Avril, Wendt, Bernd and Warne, Mark (2005). Preparation of aroyl-O-piperidine derivatives as microsomal triglyceride transfer protein (MTP) and/or apoprotein B (ApoB) inhibitors useful in the treatment of dyslipidemia and related diseases. WO2005121091.

Preparation of aroyl-O-piperidine derivatives as microsomal triglyceride transfer protein (MTP) and/or apoprotein B (ApoB) inhibitors useful in the treatment of dyslipidemia and related diseases

2004

Other Outputs

N-Benzodioxolyl, N-benzodioxanyl and N -benzodioxepinyl arylcarboxamide derivatives and pharmaceutical compositions comprising them

Dumas, Herve, Barbanton, Jacques, Collonges, Francois, Decerprit, Jacques, Ortholand, Jean-Yves, Benzies, David, Cameron, Stuart, Foster, Richard, Guessregen, Stefan, Kane, Peter, Lainton, Julia, Robertson, Avril, Wendt, Bernd and Warne, v (2004). N-Benzodioxolyl, N-benzodioxanyl and N -benzodioxepinyl arylcarboxamide derivatives and pharmaceutical compositions comprising them. WO2004037806.

N-Benzodioxolyl, N-benzodioxanyl and N -benzodioxepinyl arylcarboxamide derivatives and pharmaceutical compositions comprising them

2003

Journal Article

The Bohlmann–Rahtz route to functionalised pyridine scaffolds and their use in library synthesis

Bashford, Katherine E., Burton, Matthew B., Cameron, Stuart, Cooper, Anthony L., Hogg, Rebecca D., Kane, Peter D., MacManus, David A., Matrunola, Christopher A., Moody, Christopher J., Robertson, Avril A. B. and Warne, Mark R. (2003). The Bohlmann–Rahtz route to functionalised pyridine scaffolds and their use in library synthesis. Tetrahedron Letters, 44 (8), 1627-1629. doi: 10.1016/S0040-4039(03)00034-0

The Bohlmann–Rahtz route to functionalised pyridine scaffolds and their use in library synthesis

2001

Journal Article

High-performance liquid chromatographic separation of natural and synthetic desulphoglucosinolates and their chemical validation by UV, NMR and chemical ionisation-MS methods

Kiddle, Guy, Bennett, Richard N., Botting, Nigel P., Davidson, Nicola E., Robertson, Avril A. B. and Wallsgrove, Roger M. (2001). High-performance liquid chromatographic separation of natural and synthetic desulphoglucosinolates and their chemical validation by UV, NMR and chemical ionisation-MS methods. Phytochemical Analysis, 12 (4), 226-242. doi: 10.1002/pca.589

High-performance liquid chromatographic separation of natural and synthetic desulphoglucosinolates and their chemical validation by UV, NMR and chemical ionisation-MS methods

2000

Journal Article

Evaluation of liquid chromatography–atmospheric pressure chemical ionisation–mass spectrometry for the identification and quantification of desulphoglucosinolates

Griffiths, D. W., Bain, H., Deighton, N., Botting, N. P. and Avril Robertson (2000). Evaluation of liquid chromatography–atmospheric pressure chemical ionisation–mass spectrometry for the identification and quantification of desulphoglucosinolates. Phytochemical Analysis, 11 (4), 216-225. doi: 10.1002/1099-1565(200007/08)11:43.3.CO;2-U

Evaluation of liquid chromatography–atmospheric pressure chemical ionisation–mass spectrometry for the identification and quantification of desulphoglucosinolates

1999

Journal Article

Synthesis of deuterium labelled desulfoglucosinolates as internal standards for LC-MS analysis

Robertson, Avril and Botting, Nigel P. (1999). Synthesis of deuterium labelled desulfoglucosinolates as internal standards for LC-MS analysis. Tetrahedron, 55 (46), 13269-13284. doi: 10.1016/S0040-4020(99)00817-0

Synthesis of deuterium labelled desulfoglucosinolates as internal standards for LC-MS analysis

Current funding

  • 2022 - 2025
    Inhibiting ASC with small molecules for treatment of inflammatory diseases
    NHMRC IDEAS Grants
    Open grant

Past funding

  • 2022 - 2023
    Targeting inflammation to treat dementia (Lead by La Trobe)
    The Cass Foundation Limited
    Open grant
  • 2021 - 2024
    The NLRP3 inflammasome in the pathogenesis of polycystic kidney disease (PKD Australia administered by La Trobe University)
    La Trobe University
    Open grant
  • 2020 - 2023
    Novel Broad Spectrum Antifungals Active Against Drug Resistant Candida Auris
    NHMRC IDEAS Grants
    Open grant
  • 2018 - 2022
    Validating the NLRP3 Inflammasome as a Therapeutic Target in Motor Neuron Disease
    NHMRC Project Grant
    Open grant
  • 2017 - 2018
    A Pharmacology Screening Facility to Accelerate Drug Discovery and Development
    UQ Major Equipment and Infrastructure
    Open grant
  • 2017 - 2019
    Inflammatory pathways to liver fibrosis in non-alcoholic and alcoholic steatohepatitis: reversal by NLRP3 inhibitors (NHMRC Project Grant administered by ANU)
    Australian National University
    Open grant
  • 2017 - 2021
    Novel NLRP3 inhibitors for asthma therapy
    NHMRC Development Grant
    Open grant
  • 2016 - 2020
    Blocking inflammasome-induced neuroinflammation in PD with a potent, orally available small molecule
    The Michael J Fox Foundation Therapeutic Pipeline Program
    Open grant
  • 2015 - 2017
    Pharmacological targeting of the NLRP3 inflammasome in pre-clinical models of Parkinson's disease using a potent orally active inhibitor
    The Michael J Fox Foundation for Parkinsons Research
    Open grant
  • 2015 - 2017
    Inhibitors of NLRP3 activation for treatment of inflammatory CNS diseases
    NHMRC Project Grant
    Open grant
  • 2013 - 2016
    Novel immunomodulatory agents for type II diabetes through targeting the NLRP3 inflammasome signalling cascade
    Department of Innovation, Industry, Science and Research - Australia-India Strategic Research Fund
    Open grant
  • 2012 - 2013
    IMPDH as an antifungal drug target
    Therapeutic Innovation Australia Limited
    Open grant

Availability

Professor Avril Robertson is:
Available for supervision

Before you email them, read our advice on how to contact a supervisor.

Supervision history

Current supervision

Completed supervision

Enquiries

For media enquiries about Professor Avril Robertson's areas of expertise, story ideas and help finding experts, contact our Media team:

communications@uq.edu.au